India’s prestigious institute IIT – Delhi has unveiled a human-computer interface hand-exoskeleton device named RoboExo SMART.
The Robotic Exoskeleton device for upper limb rehabilitation was designed and developed by Prof (Dr) Amit Mehndiratta and Dr Neha Singh along with a team in the Centre of Biomedical Engineering (CBME) at IIT – Delhi.
This device will help alleviate the paralysing effects of strokes which is a leading cause of disability and death worldwide, affecting millions of people every year.
A statement from IIT- Delhi said:
“Stroke is a debilitating condition that severely impacts the brain functions of the patient, making him/her paralyzed for the rest of the life. This life-altering affliction has found a revolutionary and powerful solution in the world of medical technology.”
This device will now go through clinical trial studies for international acceptability in Australia.
This study will be conducted in collaboration with Proxmed Pty Ltd. and Prof. Mark Parsons from the Department of Medicine and Neurology, Liverpool Hospital, University of New South Wales.
This collaboration has been made possible through the Foundation for Innovation and Technology Transfer (FITT), an industry-academia interface at IIT Delhi.
Prof. Amit Mehndiratta, Centre of Biomedical Engineering (CBME) at IIT – Delhi added:
“The collaboration with Proxmed Pty. Ltd. Australia heralds an exciting chapter. The exoskeleton’s journey to Australian shores for clinical trials marks a pivotal step towards global recognition and efficacy validation. Together, both entities will propel stroke rehabilitation into an era of unparalleled possibilities.”
As per reports, the RoboExo SMART synchronises finger joint and wrist movements, minimising muscle rigidity, and enhancing daily functions.
The interface is controlled by muscle activity, with realtime performance feedback and adaptable settings, that reduces the recovery time for patients.
IIT – Delhi researchers have designed this device to improve accessibility in resource-restricted regions.
The device has undergone various stages of evaluation and is currently at national clinical validation at AIIMS in New Delhi.
Support Our Journalism
Global Indian Diaspora needs fair, non-hyphenated, and questioning journalism, packed with on-ground reporting. The Australia Today – with exceptional reporters, columnists, and editors – is doing just that. Sustaining this needs support from wonderful readers like you.
Whether you live in Australia, the United Kingdom, Canada, the United States of America, or India you can take a paid subscription by clicking Patreon. Buy an annual ‘The Australia Today Membership’ to support independent journalism and get special benefits.